Skip to Main Content

Paper Details

Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials.
Eur J Heart Fail
6
2023
Cardiomyopathy, DAPA, Dapagliflozin, HF, Participant, Patients, cardiovascular, dapagliflozin, heart failure, natriuretic peptides, participant, participants, patients
Author NameAffiliation
Mikhail KosiborodSaint Luke's Mid America Heart Institute, University of Missouri-Kansas City
Carolyn S P LamSingapore and Duke-National University of Singapore
Adrian F HernandezDuke University Medical Center
Rudolf A de BoerErasmus University Medical Center
Akshay S DesaiBrigham and Women's Hospital, Harvard Medical School
  • 1 - 5

Datasets

Release 1.2